Journey Medical Corporation Announces Presentation Of Data From Phase 1 Clinical Trial Assessing The Impact Of DFD-29 On Microbial Flora Of Healthy Adults At 2024 AAD Annual Meeting; Clinical Trial Achieved All Three Primary Objectives And Subjects Completed 16-Week Treatment With No Significant Safety Issues

Never miss a trade again with the fastest news alerts in the world!

This headline only article is a sample of real-time intelligence Benzinga Pro traders use to win in the markets everyday.

Want the fastest, most accurate stock market intelligence? Want EXCLUSIVE stories originated by Benzinga reporters? Join 10,000+ serious traders in the Benzinga Pro community!